<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinmed</journal-id><journal-title-group><journal-title xml:lang="ru">Клиническая медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical Medicine (Russian Journal)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0023-2149</issn><issn pub-type="epub">2412-1339</issn><publisher><publisher-name>ООО «Медицинское информационное агентство»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/0023-2149-2022-100-9-10-432-438</article-id><article-id custom-type="elpub" pub-id-type="custom">clinmed-440</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Факторы риска развития сердечно-сосудистых осложнений при хронической болезни почек</article-title><trans-title-group xml:lang="en"><trans-title>Risk factors for cardiovascular complications in chronic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8387-5800</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабиров</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sabirov</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сабиров Ибрагим Самижонович — доктор медицинских наук, профессор, заведующий кафедрой терапии № 2 медицинского факультета КРСУ им. Б.Н. Ельцина.</p><p>720000, Бишкек</p></bio><bio xml:lang="en"><p>Sabirov Ibrahim S.</p><p>720040, Bishkek</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7653-0433</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муркамилова</surname><given-names>Ж. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Murkamilova</surname><given-names>J. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Муркамилова Жамила Абдилалимовна — заочный аспирант кафедры терапии №2 медицинского факультета КРСУ им. Б.Н. Ельцина.</p><p>720000, Бишкек</p></bio><bio xml:lang="en"><p>Murkamilova Jamila A.</p><p>720040, Bishkek</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8055-6233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабирова</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sabirova</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сабирова Азиза Ибрагимовна — кандидат медицинских наук, и.о. доцента кафедры хирургической стоматологии КРСУ им. Б.Н. Ельцина.</p><p>720000, Бишкек</p></bio><bio xml:lang="en"><p>Sabirova Aziza I.</p><p>720040, Bishkek</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8513-9279</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муркамилов</surname><given-names>И. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Murkamilov</surname><given-names>I. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Муркамилов Илхом Торобекович — доктор медицинских наук, доцент кафедры факультетской терапии КГМА им. И.К. Ахунбаева; старший преподаватель ГОУ ВПО Кыргызско-РСУ, нефролог, председатель правления Общества специалистов по хронической болезни почек Кыргызстана.</p><p>720000, 720020, Бишкек</p></bio><bio xml:lang="en"><p>Murkamilov Ilkhom T.</p><p>720040, 720020, Bishkek</p></bio><email xlink:type="simple">murkamilov.i@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2682-4417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомин Виктор Викторович — доктор медицинских наук, профессор, член-корр. РАН, заведующий кафедрой факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского, проректор по инновационной и клинической деятельности, ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» МР.</p><p>119991, Москва</p></bio><bio xml:lang="en"><p>Fomin Viktor V.</p><p>119991, Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0632-6653</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юсупов</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yusupov</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юсупов Фуркат Абдулахатович — доктор медицинских наук, профессор, заведующий кафедрой неврологии, нейрохирургии и психиатрии медицинского факультета Ошского ГУ, член правления Общества специалистов по хронической болезни почек Кыргызстана, главный невролог Южного Кыргызстана.</p><p>723500, Ош</p></bio><bio xml:lang="en"><p>Yusupov Furkat A.</p><p>723500, Osh</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГОУ ВПО Кыргызско-Российский славянский университет имени первого Президента Российской Федерации Б.Н. Ельцина</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Scientifi c and Research Institute of Molecular Biology and Medicine</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГОУ ВПО Кыргызско-Российский славянский университет имени первого Президента Российской Федерации Б.Н. Ельцина; Кыргызская государственная медицинская академия имени И.К. Ахунбаева</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Scientifi c and Research Institute of Molecular Biology and Medicine; I.K. Akhunbaev Kyrgyz State Medical Academy</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Ошский государственный университет</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Osh State University</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2022</year></pub-date><volume>100</volume><issue>9-10</issue><fpage>432</fpage><lpage>438</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сабиров И.С., Муркамилова Ж.А., Сабирова А.И., Муркамилов И.Т., Фомин В.В., Юсупов Ф.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Сабиров И.С., Муркамилова Ж.А., Сабирова А.И., Муркамилов И.Т., Фомин В.В., Юсупов Ф.А.</copyright-holder><copyright-holder xml:lang="en">Sabirov I.S., Murkamilova J.A., Sabirova A.I., Murkamilov I.T., Fomin V.V., Yusupov F.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinmedjournal.com/jour/article/view/440">https://www.clinmedjournal.com/jour/article/view/440</self-uri><abstract><p>Факторы риска представляют собой индивидуальные особенности организма и поведения человека, оказывающие влияние на возможность развития в будущем заболевания и/или патологического состояния. В отношении определенных нозологических единиц, в том числе и сердечно-сосудистых заболеваний, различают модифицируемые и немодифицируемые факторы риска. К немодифицируемым факторам риска развития и прогрессирования сердечнососудистых заболеваний относятся возраст, пол и генетическая предрасположенность, которые используют для разработки систем стратификации риска развития кардиоваскулярной патологии. Эти факторы не могут быть скорректированы, т.е. модифицированы, их только можно учитывать при определении степени риска развития заболеваний. Напротив, модифицируемые факторы риска развития и прогрессирования патологии сердечно-сосудистой системы могут подвергаться изменениям и подразделяются на поведенческие и биологические. К поведенческим факторам относят курение, нездоровое питание, низкую физическую активность, избыточное потребление алкоголя, хроническое психоэмоциональное напряжение. В условиях урбанизации поведенческие факторы риска, способствующие развитию сердечно-сосудистых заболеваний, в жизни современного человека встречаются все более часто. Следует отметить, что при длительном воздействии поведенческих факторов риска на организм человека происходит формирование уже и биологических факторов — артериальной гипертензии, дислипидемии, избыточной массы тела, ожирения и сахарного диабета, хронической болезни почек, являющихся значимыми для развития сердечно-сосудистой патологии. В данной обзорной статье обсуждаются вопросы вклада хронической болезни почек как фактора риска, а также механизмов формирования и прогрессирования сердечно-сосудистых заболеваний при дисфункции почек.</p></abstract><trans-abstract xml:lang="en"><p>Risk factors are constitutional peculiarity and human behavior that infl uence the disease development and / or pathological condition in the future. With regard to certain nosological units, including cardiovascular diseases, modifi able and nonmodifi able risk factors are distinguished. Non-modifi able risk factors for the development and progression of cardiovascular diseases include age, gender, and genetic predisposition, which are used to develop risk stratifi cation systems. These risk factors cannot be adjusted, ie. modifi ed, and can only be taken into account when determining the level of risk of diseases development. On the contrary, modifi able risk factors can undergo changes and be subdivided into behavioral and biological ones. Behavioral risk factors include: smoking, unhealthy diet, low physical activity, excessive alcohol consumption, chronic psycho-emotional stress. These behavioral risk factors in the lifestyle of a modern person are becoming more common in the conditions of urbanization, and contribute to the development of cardiovascular diseases. It should be noted that with longterm exposure to behavioral risk factors on the human body, biological risk factors are also formed: arterial hypertension, dyslipidemia, overweight, obesity, diabetes mellitus, chronic kidney disease.This review discusses the contribution of chronic kidney disease as a risk factor, as well as the mechanisms of formation and progression of cardiovascular diseases in kidney dysfunction.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>обзор</kwd><kwd>факторы риска</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>хроническая болезнь почек</kwd><kwd>воспаление</kwd><kwd>эндотоксинемия</kwd><kwd>окислительный стресс</kwd><kwd>старение</kwd><kwd>протеинурия</kwd><kwd>резистентность к инсулину</kwd><kwd>гиперфосфатемия</kwd><kwd>эндотелиальная дисфункция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>review</kwd><kwd>risk factors</kwd><kwd>cardiovascular disease</kwd><kwd>chronic kidney disease</kwd><kwd>inflammation</kwd><kwd>endotoxinemia</kwd><kwd>oxidative stress</kwd><kwd>aging</kwd><kwd>proteinuria</kwd><kwd>insulin resistance</kwd><kwd>hyperphosphatemia</kwd><kwd>endothelial dysfunction</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The study had no sponsorship</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cardiovascular diseases. World Health Organization, 2020. [Electronic resource]. URL: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1. Accessed: 20 Jan 2021.</mixed-citation><mixed-citation xml:lang="en">Cardiovascular diseases. World Health Organization, 2020. [Electronic resource]. URL: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1. Accessed: 20 Jan 2021.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бунова С., Охотникова П., Скирденко Ю. и др. COVID-19 и сердечно-сосудистая коморбидность: поиск новых подходов к снижению смертности. Кардиоваскулярная терапия и профилактика. 2021;20(4):2953. DOI: 10.15829/1728-8800-2021-2953</mixed-citation><mixed-citation xml:lang="en">Bunova S., Okhotnikova P., Skirdenko Yu. et al. COVID-19 and cardiovascular comorbidity: the search for new approaches to reduce mortality. Cardiovascular therapy and prevention. 2021;20(4):2953. (In Russian). DOI: 10.15829/1728-8800-2021-2953</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hill N., Fatoba S. Oke J. et al. Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. DOI: 10.1371/journal.pone.0158765</mixed-citation><mixed-citation xml:lang="en">Hill N., Fatoba S. Oke J. et al. Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. DOI: 10.1371/journal.pone.0158765</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classifi cation, and stratifi cation. Am. J. Kidney Dis. 2002;39(1):S1–S266.</mixed-citation><mixed-citation xml:lang="en">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classifi cation, and stratifi cation. Am. J. Kidney Dis. 2002;39(1):S1–S266.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zalups R., Diamond G. Mercuric chloride-induced nephrotoxicity in the rat following unilateral nephrectomy and compensatory renal growth. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1987;53(6):336–46. DOI: 10.1007/BF02890261</mixed-citation><mixed-citation xml:lang="en">Zalups R., Diamond G. Mercuric chloride-induced nephrotoxicity in the rat following unilateral nephrectomy and compensatory renal growth. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1987;53(6):336–46. DOI: 10.1007/BF02890261</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Parikh N., Hwang S., Larson M. et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 2006;166(17):1884–91. DOI: 10.1001/archinte.166.17.1884</mixed-citation><mixed-citation xml:lang="en">Parikh N., Hwang S., Larson M. et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 2006;166(17):1884–91. DOI: 10.1001/archinte.166.17.1884</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Coresh J., Astor B., Greene T. et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003;41(1):1–12. DOI: 10.1053/ajkd.2003.50007</mixed-citation><mixed-citation xml:lang="en">Coresh J., Astor B., Greene T. et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003;41(1):1–12. DOI: 10.1053/ajkd.2003.50007</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Go A., Chertow G., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351:1296–1305. DOI: 10.1056/NEJMoa041031</mixed-citation><mixed-citation xml:lang="en">Go A., Chertow G., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351:1296–1305. DOI: 10.1056/NEJMoa041031</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kerr M., Bray B., Medcalf J. et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrology Dialysis Transplantation. 2012;27(3):73–80.</mixed-citation><mixed-citation xml:lang="en">Kerr M., Bray B., Medcalf J. et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrology Dialysis Transplantation. 2012;27(3):73–80.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chronic Kidney Disease Prognosis Consortium, Matsushita K., van der Velde M., Astor B. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. DOI: 10.1016/S0140-6736(10)60674-5</mixed-citation><mixed-citation xml:lang="en">Chronic Kidney Disease Prognosis Consortium, Matsushita K., van der Velde M., Astor B. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. DOI: 10.1016/S0140-6736(10)60674-5</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82. DOI: 10.1136/bmj.39609.449676.25</mixed-citation><mixed-citation xml:lang="en">Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82. DOI: 10.1136/bmj.39609.449676.25</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Goff D.Jr., Lloyd-Jones D., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014;63(25 Pt B):2935–2959. DOI: 10.1016/j.jacc.2013.11.005</mixed-citation><mixed-citation xml:lang="en">Goff D.Jr., Lloyd-Jones D., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014;63(25 Pt B):2935–2959. DOI: 10.1016/j.jacc.2013.11.005</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tangri N., Kitsios G., Inker L. et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann. Intern. Med. 2013;158(8):596–603. DOI: 10.7326/0003-4819-158-8-201304160-00004</mixed-citation><mixed-citation xml:lang="en">Tangri N., Kitsios G., Inker L. et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann. Intern. Med. 2013;158(8):596–603. DOI: 10.7326/0003-4819-158-8-201304160-00004</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Major R., Cheng M., Grant R. et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS ONE. 2018;13(3):e0192895. DOI: 10.1371/journal.pone.0192895</mixed-citation><mixed-citation xml:lang="en">Major R., Cheng M., Grant R. et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS ONE. 2018;13(3):e0192895. DOI: 10.1371/journal.pone.0192895</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Matsushita K., Coresh J., Sang Y. et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3:514–525. DOI: 10.1016/S2213-8587(15)00040-6</mixed-citation><mixed-citation xml:lang="en">Matsushita K., Coresh J., Sang Y. et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3:514–525. DOI: 10.1016/S2213-8587(15)00040-6</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffrin E., Lipman M., Mann J. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97. DOI: 10.1161/CIRCULATIONAHA.106.678342</mixed-citation><mixed-citation xml:lang="en">Schiffrin E., Lipman M., Mann J. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97. DOI: 10.1161/CIRCULATIONAHA.106.678342</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Menon V., Gul A., Sarnak M. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005;68(4):1413–1418. pmid:16164615.</mixed-citation><mixed-citation xml:lang="en">Menon V., Gul A., Sarnak M. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005;68(4):1413–1418. pmid:16164615.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Covic A., Kothawala P., Bernal M. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol. Dial. Transplant. 2009;24(5):1506–1523. pmid:19001560.</mixed-citation><mixed-citation xml:lang="en">Covic A., Kothawala P., Bernal M. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol. Dial. Transplant. 2009;24(5):1506–1523. pmid:19001560.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">London G., Pannier B., Guerin A. et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J. Am. Soc. Nephrol. 2001;12(12):2759–2767. DOI: 10.1681/ASN.V12122759</mixed-citation><mixed-citation xml:lang="en">London G., Pannier B., Guerin A. et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J. Am. Soc. Nephrol. 2001;12(12):2759–2767. DOI: 10.1681/ASN.V12122759</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S., Huang J., Su H. et al. Prognostic cardiovascular markers in chronic kidney disease. Kidney Blood Press Res. 2018;43:1388–1407. DOI: 10.1159/000492953</mixed-citation><mixed-citation xml:lang="en">Chen S., Huang J., Su H. et al. Prognostic cardiovascular markers in chronic kidney disease. Kidney Blood Press Res. 2018;43:1388–1407. DOI: 10.1159/000492953</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cottone S., Lorito M., Riccobene R. et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J. Nephrol. 2008;21(2):175–9. pmid: 18446711.</mixed-citation><mixed-citation xml:lang="en">Cottone S., Lorito M., Riccobene R. et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J. Nephrol. 2008;21(2):175–9. pmid: 18446711.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Oishi Y., Manabe I. Macrophages in age-related chronic inflammatory diseases. NPJ Aging Mech. Dis. 2016;2:16018. DOI: 10.1038/npjamd.2016.18</mixed-citation><mixed-citation xml:lang="en">Oishi Y., Manabe I. Macrophages in age-related chronic inflammatory diseases. NPJ Aging Mech. Dis. 2016;2:16018. DOI: 10.1038/npjamd.2016.18</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Silverstein D. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr. Nephrol. 2009;24:1445–1452. DOI: 10.1007/s00467-008-1046-0</mixed-citation><mixed-citation xml:lang="en">Silverstein D. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr. Nephrol. 2009;24:1445–1452. DOI: 10.1007/s00467-008-1046-0</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sproston N., Ashworth J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 2018;9:754. DOI: 10.3389/fimmu.2018.00754</mixed-citation><mixed-citation xml:lang="en">Sproston N., Ashworth J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 2018;9:754. DOI: 10.3389/fimmu.2018.00754</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Stenvinkel P., Larsson T. Chronic kidney disease: a clinical model of premature aging. Am. J. Kidney Dis. 2013;62:339–351. DOI: 10.1053/j.ajkd.2012.11.051</mixed-citation><mixed-citation xml:lang="en">Stenvinkel P., Larsson T. Chronic kidney disease: a clinical model of premature aging. Am. J. Kidney Dis. 2013;62:339–351. DOI: 10.1053/j.ajkd.2012.11.051</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wu I., Hsu K., Lee C. et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol. Dial. Transplant. 2011;26:938–947. DOI: 10.1093/ndt/gfq580</mixed-citation><mixed-citation xml:lang="en">Wu I., Hsu K., Lee C. et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol. Dial. Transplant. 2011;26:938–947. DOI: 10.1093/ndt/gfq580</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ramezani A., Raj D. The gut microbiome, kidney disease, and targeted interventions. J. Am. Soc. Nephrol. 2014;25:657–670. DOI: 10.1681/ASN.2013080905</mixed-citation><mixed-citation xml:lang="en">Ramezani A., Raj D. The gut microbiome, kidney disease, and targeted interventions. J. Am. Soc. Nephrol. 2014;25:657–670. DOI: 10.1681/ASN.2013080905</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sirich T., Meyer T., Gondouin B. et al. Protein-bound molecules: a large family with a bad character. Semin. Nephrol. 2014;34:106–117. DOI: 10.1016/j.semnephrol.2014.02.004</mixed-citation><mixed-citation xml:lang="en">Sirich T., Meyer T., Gondouin B. et al. Protein-bound molecules: a large family with a bad character. Semin. Nephrol. 2014;34:106–117. DOI: 10.1016/j.semnephrol.2014.02.004</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sies H. Biochemistry of Oxidative Stress. Angew. Chem. Int. Ed. Engl. 1986;25:1058–1071. DOI: 10.1002/anie.198610581</mixed-citation><mixed-citation xml:lang="en">Sies H. Biochemistry of Oxidative Stress. Angew. Chem. Int. Ed. Engl. 1986;25:1058–1071. DOI: 10.1002/anie.198610581</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cachofeiro V., de Goicochea M., Vinuesa S. et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008;74:S4–S9. DOI: 10.1038/ki.2008.516</mixed-citation><mixed-citation xml:lang="en">Cachofeiro V., de Goicochea M., Vinuesa S. et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008;74:S4–S9. DOI: 10.1038/ki.2008.516</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mihai S., Codrici E., Popescu I. et al. Inflammation-related mechanisms in chronic kidney disease prediction, Progression, and outcome. J. Immunol. Res. 2018:2180373. DOI: 10.1155/2018/2180373</mixed-citation><mixed-citation xml:lang="en">Mihai S., Codrici E., Popescu I. et al. Inflammation-related mechanisms in chronic kidney disease prediction, Progression, and outcome. J. Immunol. Res. 2018:2180373. DOI: 10.1155/2018/2180373</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Liakopoulos V., Roumeliotis S., Zarogiannis S. et al. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin. Dial. 2019;32:58–71. DOI: 10.1111/sdi.12745</mixed-citation><mixed-citation xml:lang="en">Liakopoulos V., Roumeliotis S., Zarogiannis S. et al. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin. Dial. 2019;32:58–71. DOI: 10.1111/sdi.12745</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Merino A., Buendia P., Martin-Malo A. et al. Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J. Immunol. 2011;186:1809–1815. DOI: 10.4049/jimmunol.1001866</mixed-citation><mixed-citation xml:lang="en">Merino A., Buendia P., Martin-Malo A. et al. Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J. Immunol. 2011;186:1809–1815. DOI: 10.4049/jimmunol.1001866</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Carracedo J., Alique M., Ramirez-Carracedo R. et al. Endothelial extracellular vesicles produced by senescent cells: pathophysiological role in the cardiovascular disease associated with all types of diabetes mellitus. Curr. Vasc. Pharmacol. 2018;17:447–454. DOI: 10.2174/1570161116666180820115726</mixed-citation><mixed-citation xml:lang="en">Carracedo J., Alique M., Ramirez-Carracedo R. et al. Endothelial extracellular vesicles produced by senescent cells: pathophysiological role in the cardiovascular disease associated with all types of diabetes mellitus. Curr. Vasc. Pharmacol. 2018;17:447–454. DOI: 10.2174/1570161116666180820115726</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">López-Otín C., Blasco M., Partridge L. et al. The hallmarks of aging. Cell. 2013;153:1194–1217. DOI: 10.1016/j.cell.2013.05.039</mixed-citation><mixed-citation xml:lang="en">López-Otín C., Blasco M., Partridge L. et al. The hallmarks of aging. Cell. 2013;153:1194–1217. DOI: 10.1016/j.cell.2013.05.039</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Shimizu I., Minamino T. Cellular senescence in cardiac diseases. J. Cardiol. 2019;74:313–319. DOI: 10.1016/j.jjcc.2019.05.002</mixed-citation><mixed-citation xml:lang="en">Shimizu I., Minamino T. Cellular senescence in cardiac diseases. J. Cardiol. 2019;74:313–319. DOI: 10.1016/j.jjcc.2019.05.002</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Stenvinkel P., Larsson T. Chronic kidney disease: a clinical model of premature aging. Am. J. Kidney Dis. 2013;62:339–351. DOI: 10.1053/j.ajkd.2012.11.051</mixed-citation><mixed-citation xml:lang="en">Stenvinkel P., Larsson T. Chronic kidney disease: a clinical model of premature aging. Am. J. Kidney Dis. 2013;62:339–351. DOI: 10.1053/j.ajkd.2012.11.051</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Popolo A., Autore G., Pinto A., Marzocco S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic. Res. 2013;47:346–356. DOI: 10.3109/10715762.2013.779373</mixed-citation><mixed-citation xml:lang="en">Popolo A., Autore G., Pinto A., Marzocco S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic. Res. 2013;47:346–356. DOI: 10.3109/10715762.2013.779373</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Currie G., Delles C. Proteinuria and its relation to cardiovascular disease. International journal of nephrology and renovascular disease. 2013;7:13–24. DOI:10.2147/IJNRD.S40522</mixed-citation><mixed-citation xml:lang="en">Currie G., Delles C. Proteinuria and its relation to cardiovascular disease. International journal of nephrology and renovascular disease. 2013;7:13–24. DOI:10.2147/IJNRD.S40522</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner D., Harris T., Madans J. Proteinuria as a biomarker: risk of subsequent morbidity and mortality. Environ. Res. 1994;66(2):160–72. DOI: 10.1006/enrs.1994.1052</mixed-citation><mixed-citation xml:lang="en">Wagner D., Harris T., Madans J. Proteinuria as a biomarker: risk of subsequent morbidity and mortality. Environ. Res. 1994;66(2):160–72. DOI: 10.1006/enrs.1994.1052</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Hillege H., Janssen W., Bak A. et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. 2001;249(6):519–26. DOI: 10.1046/j.1365-2796.2001.00833.x</mixed-citation><mixed-citation xml:lang="en">Hillege H., Janssen W., Bak A. et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. 2001;249(6):519–26. DOI: 10.1046/j.1365-2796.2001.00833.x</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Wachtell K., Ibsen H., Olsen M. et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 2003;139(11):901–6. DOI: 10.7326/0003-4819-139-11-200312020-00008</mixed-citation><mixed-citation xml:lang="en">Wachtell K., Ibsen H., Olsen M. et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 2003;139(11):901–6. DOI: 10.7326/0003-4819-139-11-200312020-00008</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Lee M., Saver J., Chang K. et al. Impact of microalbuminuria on incident stroke: a meta-analysis. Stroke. 2010;41(11):2625–31. DOI: 10.1161/STROKEAHA.110.581215</mixed-citation><mixed-citation xml:lang="en">Lee M., Saver J., Chang K. et al. Impact of microalbuminuria on incident stroke: a meta-analysis. Stroke. 2010;41(11):2625–31. DOI: 10.1161/STROKEAHA.110.581215</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Deckert T., Feldt-Rasmussen B., Borch-Johnsen K. et al. Albuminuria refl ects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32(4):219–26. DOI: 10.1007/BF00285287</mixed-citation><mixed-citation xml:lang="en">Deckert T., Feldt-Rasmussen B., Borch-Johnsen K. et al. Albuminuria refl ects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32(4):219–26. DOI: 10.1007/BF00285287</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Hellemons M., Lambers Heerspink H., Gansevoort R. et al. Highsensitivity troponin T predicts worsening of albuminuria in hyper tension; results of a nested case-control study with confirmation in diabetes. J. Hypertens. 2013;31(4):805–12. DOI: 10.1097/HJH.0b013e32835eb5e8</mixed-citation><mixed-citation xml:lang="en">Hellemons M., Lambers Heerspink H., Gansevoort R. et al. Highsensitivity troponin T predicts worsening of albuminuria in hyper tension; results of a nested case-control study with confirmation in diabetes. J. Hypertens. 2013;31(4):805–12. DOI: 10.1097/HJH.0b013e32835eb5e8</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz M., Sonmez A., Saglam M. et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J. Am. Soc. Nephrol. 2008;19(2):388–95. DOI: 10.1681/ASN.2007040461</mixed-citation><mixed-citation xml:lang="en">Yilmaz M., Sonmez A., Saglam M. et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J. Am. Soc. Nephrol. 2008;19(2):388–95. DOI: 10.1681/ASN.2007040461</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Stehouwer C., Gall M., Twisk J. et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157–65. DOI: 10.2337/diabetes.51.4.1157</mixed-citation><mixed-citation xml:lang="en">Stehouwer C., Gall M., Twisk J. et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157–65. DOI: 10.2337/diabetes.51.4.1157</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Hirano T., Kashiwazaki K., Moritomo Y. et al. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 1997;36(1):11–8. DOI: 10.1016/s0168-8227(97)01384-3</mixed-citation><mixed-citation xml:lang="en">Hirano T., Kashiwazaki K., Moritomo Y. et al. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 1997;36(1):11–8. DOI: 10.1016/s0168-8227(97)01384-3</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Mykkänen L., Zaccaro D., Wagenknecht L. et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 1998;47(5):793–800. DOI: 10.2337/diabetes.47.5.793</mixed-citation><mixed-citation xml:lang="en">Mykkänen L., Zaccaro D., Wagenknecht L. et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 1998;47(5):793–800. DOI: 10.2337/diabetes.47.5.793</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Bianchi S., Bigazzi R., Valtriani C. et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension. 1994;23(6 Pt 1):681–7. DOI: 10.1161/01.hyp.23.6.681</mixed-citation><mixed-citation xml:lang="en">Bianchi S., Bigazzi R., Valtriani C. et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension. 1994;23(6 Pt 1):681–7. DOI: 10.1161/01.hyp.23.6.681</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Pinto-Sietsma S., Navis G., Janssen W. et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am. J. Kidney Dis. 2003;41(4):733–41. DOI: 10.1016/s0272-6386(03)00020-9</mixed-citation><mixed-citation xml:lang="en">Pinto-Sietsma S., Navis G., Janssen W. et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am. J. Kidney Dis. 2003;41(4):733–41. DOI: 10.1016/s0272-6386(03)00020-9</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int. Suppl. 2005;(99):S25–9. DOI: 10.1111/j.1523-1755.2005.09906.x</mixed-citation><mixed-citation xml:lang="en">Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int. Suppl. 2005;(99):S25–9. DOI: 10.1111/j.1523-1755.2005.09906.x</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou C., Shi Z., Ouyang N., Ruan X. Hyperphosphatemia and Cardio vascular Disease. Front Cell Dev. Biol. 2021;9:644363. DOI: 10.3389/fcell.2021.644363</mixed-citation><mixed-citation xml:lang="en">Zhou C., Shi Z., Ouyang N., Ruan X. Hyperphosphatemia and Cardio vascular Disease. Front Cell Dev. Biol. 2021;9:644363. DOI: 10.3389/fcell.2021.644363</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Takashi Y., Fukumoto S. Fibroblast growth factor receptor as a potential candidate for phosphate sensing. Curr. Opin. Nephro.l Hypertens. 2020;29(4):446–452. DOI: 10.1097/MNH.0000000000000618</mixed-citation><mixed-citation xml:lang="en">Takashi Y., Fukumoto S. Fibroblast growth factor receptor as a potential candidate for phosphate sensing. Curr. Opin. Nephro.l Hypertens. 2020;29(4):446–452. DOI: 10.1097/MNH.0000000000000618</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz M., Saglam M., Caglar K. et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 2006;47:42–50. DOI: 10.1053/j.ajkd.2005.09.029</mixed-citation><mixed-citation xml:lang="en">Yilmaz M., Saglam M., Caglar K. et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 2006;47:42–50. DOI: 10.1053/j.ajkd.2005.09.029</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhoutte P., Zhao Y., Xu A., Leung S. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. Circ. Res. 2016;119:375–396. DOI: 10.1161/CIRCRESAHA.116.306531</mixed-citation><mixed-citation xml:lang="en">Vanhoutte P., Zhao Y., Xu A., Leung S. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. Circ. Res. 2016;119:375–396. DOI: 10.1161/CIRCRESAHA.116.306531</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Zoccali C. Endothelial dysfunction and the kidney: Emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J. Am. Soc. Nephrol. 2006;17:561–563. DOI: 10.1681/ASN.2005121344</mixed-citation><mixed-citation xml:lang="en">Zoccali C. Endothelial dysfunction and the kidney: Emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J. Am. Soc. Nephrol. 2006;17:561–563. DOI: 10.1681/ASN.2005121344</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Милованова Л.Ю., Бекетов В.Д., Милованова С.Ю., Таранова М.В., Филиппова А.А., Пасечник А.И. Биомаркеры пора жения сердца и сосудов в рамках минерально-костных нарушений при хронической болезни почек, возможности коррекции. Клиническая медицина. 2021;99(4):245–258. DOI: 10.30629/0023-2149-2021-99-4-245-258</mixed-citation><mixed-citation xml:lang="en">Milovanova L.Yu., Beketov V.D., Milovanova S.Yu., Taranova M.V., Filippova A.A., Pasechnik A.I. Biomarkers of damage to the heart and blood vessels in the framework of mineral and bone disorders in chronic kidney disease, the possibility of correction. Clinical medicine. 2021;99(4):245–258. (In Russian). DOI: 10.30629/0023-2149-2021-99-4-245-258</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
